Mankind Pharma Limited IPO: Issue Price, Listing Gain and Share Price Now
Mankind Pharma Limited listed on 09-May-2023 at ₹1,424.05 against an issue price of ₹1,080 , a listing gain of +31.86%. It last traded at ₹2,385. This page is the record of that issue and what has happened to it since — reported figures only.
Mankind Pharma Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹1,080 |
| Listing price (listing-day close) | ₹1,424.05 |
| Listing gain | +31.86% |
| Price now | ₹2,385 |
| Change from issue price | +120.83% |
| Change from listing-day close | +67.48% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Mankind Pharma Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹1,080 |
| Issue size | ₹4,326.36 Cr |
| Offer for sale | ₹4,326.36 Cr |
| Issue opened | 25-Apr-2023 |
| Issue closed | 27-Apr-2023 |
| Listed on | 09-May-2023 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | Kotak Mahindra Capital (left lead) |
How the Mankind Pharma Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 49.16x |
| NII | 3.80x |
| Retail | 0.92x |
| Total | 15.32x |
Mankind Pharma Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹98,623 Cr |
| Trailing P/E | 46.20x |
| Return on capital employed | 13.5% |
| Return on equity | 13.1% |
| 52-week high | ₹2,674 |
| 52-week low | ₹1,910 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Mankind Pharma Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.